REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection. Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.
Study Type
OBSERVATIONAL
Enrollment
748
Screening/Management Plan
Tom Marwick
Hobart, Tasmania, Australia
RECRUITINGBaker Heart and Diabetes Institute
Melbourne, Victoria, Australia
RECRUITINGProportion of evaluated patients who should undergo CAD prevention
High clinical risk, or intermediate risk with CAC score \>0
Time frame: 3 years
Proportion with critical CAD
Coronary stenosis \>70% by CT coronary angiogram
Time frame: 3 years
Proportion at intermediate clinical risk
Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)
Time frame: 3 years
Statin responsiveness
Change in plaque volume
Time frame: 3 year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.